| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Over the last 12 months, insiders at Lisata Therapeutics, Inc. have bought $0 and sold $0 worth of Lisata Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Lisata Therapeutics, Inc. have bought $30,190 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 33,785 shares for transaction amount of $30,190 was made by MYERS STEVEN S (director) on 2021‑12‑08.
| MYERS STEVEN S | director | 146839 1.7078% | $371,502.67 | 1 | 0 | <0.0001% |
$155,580,641 | 77 | -24.21% | $23.91M | |
$17,268,389 | 57 | -18.16% | $25.73M | |
$53,490,060 | 55 | 19.35% | $19.52M | |
$395,438 | 43 | -21.25% | $22.47M | |
$1,443,732 | 36 | 10.14% | $21.07M | |
$1,995,470 | 22 | 14.01% | $22.81M | |
$25,487,383 | 15 | -4.37% | $21.6M | |
$122,973 | 15 | -26.96% | $19.25M | |
$79,536,861 | 15 | -6.81% | $20.56M | |
$389,864 | 11 | 12.52% | $19.33M | |
$309,830 | 10 | -55.78% | $19.56M | |
$20,715,938 | 10 | -42.51% | $19.33M | |
$189,648 | 9 | -52.20% | $23.88M | |
$147,504 | 5 | -36.70% | $22.2M | |
$26,000,000 | 5 | -56.00% | $22.21M | |
$1,184,658 | 4 | -22.17% | $22.68M | |
$31,190 | 2 | -14.18% | $20.35M | |
Lisata Therapeutics, Inc. (LSTA) | $30,190 | 1 | -42.39% | $21.75M |
$500,000 | 1 | -22.94% | $22.3M |
| Increased Positions | 10 | +45.45% | 90,298 | +11.49% |
| Decreased Positions | 7 | -31.82% | 92,652 | -11.79% |
| New Positions | 4 | New | 10,293 | New |
| Sold Out Positions | 2 | Sold Out | 23,274 | Sold Out |
| Total Postitions | 25 | +13.64% | 783,380 | -0.3% |
| Bml Capital Management, Llc | $686.00 | 3.16% | 284,669 | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $449.00 | 2.07% | 186,366 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $244.00 | 1.13% | 101,322 | -2,300 | -2.22% | 2024-12-31 |
| Geode Capital Management, Llc | $135.00 | 0.62% | 55,895 | +214 | +0.38% | 2024-12-31 |
| Blackrock, Inc. | $132.00 | 0.61% | 54,857 | -1,156 | -2.06% | 2025-03-31 |
| Dimensional Fund Advisors Lp | $61.00 | 0.28% | 25,226 | +7,886 | +45.48% | 2024-12-31 |
| Citadel Advisors Llc | $56.00 | 0.26% | 23,273 | +23,273 | New | 2024-12-31 |
| State Street Corp | $35.00 | 0.16% | 14,348 | 0 | 0% | 2024-12-31 |
| Cook Wealth, Llc | $29.00 | 0.14% | 12,175 | 0 | 0% | 2024-12-31 |
| Bank Of America Corp /De/ | $25.00 | 0.12% | 10,410 | +695 | +7.15% | 2024-12-31 |